Discovery
| Parameter | Value |
|---|---|
| FDA authorization date | December 11, 2020 (EUA) |
| Vaccines | BNT162b2 (BioNTech/Pfizer), mRNA-1273 (Moderna) |
| Key innovation | Pseudouridine substitution (Karikó & Weissman, 2005) |
| Dose | 30 μg (Pfizer) / 100 μg (Moderna) of mRNA |
| Initial efficacy | 95% (Pfizer) / 94.1% (Moderna) |
| Nobel Prize | 2023 (Karikó & Weissman) |
Technical Explanation
1. mRNA design — The sequence encodes the SARS-CoV-2 Spike (S) protein (1,273 amino acids). Two proline mutations (K986P + V987P) stabilize the "pre-fusion" conformation — the shape the immune system needs to recognize. The mRNA includes a 5' cap (cap1), optimized UTRs, and a poly(A) tail of ~100 nt for stability.
2. Chemical modification — Naked mRNA activates innate immune receptors TLR-3/7/8 (interferons → degradation). Replacing all uridines with N1-methylpseudouridine (m1Ψ) eliminates this recognition: the modified mRNA becomes "invisible" to antiviral sentinels, allowing translation by ribosomes.
3. Lipid nanoparticles (LNP) — The mRNA is encapsulated in ~80 nm LNPs composed of 4 lipids: ionizable lipid (ALC-0315 for Pfizer), DSPC, cholesterol, and PEG-lipid. The ionizable lipid is neutral at pH 7.4 (circulation) but becomes positively charged at pH 6 (endosome), destabilizing the endosomal membrane to release the mRNA into the cytoplasm.
4. Immune response — Ribosomes translate the mRNA into Spike protein, which is presented on the cell surface via MHC-I. Dendritic cells activate CD8+ T lymphocytes (cytotoxic response) and CD4+ T cells (B-cell help). B lymphocytes produce neutralizing anti-Spike antibodies. Immune memory: memory B and T cells persist for months to years.
Why It Worked
The breakthrough by Karikó and Weissman (2005) solved the fundamental problem: the innate immunogenicity of mRNA that had blocked every therapeutic application since the 1990s. LNP technology, developed for siRNA delivery (patisiran, 2018), provided a proven vehicle. The modular platform design (only the sequence changes) enabled Moderna to go from selecting the mRNA-1273 sequence (January 13, 2020) to the first dose administered in humans in 63 days (March 16, 2020) — that is, entry into a phase 1 trial, not the full development of the vaccine.
The speed was staggering: on January 10, 2020, the viral sequence was posted online; by January 13 — three days later — Moderna had finalized its mRNA candidate design (mRNA-1273). No sample of the actual virus was needed: the digital sequence alone sufficed. It was the first time in history that a vaccine was designed before the manufacturer possessed the pathogen.
Causal Chain
mRNA as informational molecule (Jacob & Monod, 1961) → First in vivo mRNA trials (Wolff, 1990) → Failures (inflammation) → Pseudouridine = stealth mRNA (Karikó & Weissman, 2005) → LNP for intracellular delivery (Cullis) → Cancer trials (BioNTech, 2017) → SARS-CoV-2 sequenced (January 2020) → mRNA-1273 in phase 1 in 63 days → EUA December 2020 → 13 billion doses → Nobel 2023
Anecdote
On January 10, 2020, the SARS-CoV-2 sequence was published online. On January 13 — three days later — Moderna finalized its mRNA candidate design (mRNA-1273). No sample of the virus was required: the digital sequence was enough. It was the first time in history a vaccine was designed before the manufacturer had ever handled the pathogen.
Sources
References verified during the August 2026 fact-checking audit: these are the pages
against which this bulletin's claims were checked.